Clinical Trial Update: RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating RO4929097 in combination with capecitabine in patients with refractory solid tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Breast Cancer
• Burkitt Lymphoma
• Colon Cancer
• Diffuse Large B-cell Lymphoma
• Marginal Zone Lymphoma
• Mycosis Fungoides Sezary Syndrome
• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• RO4929097 (RO4929097)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Status: COMPLETED